If you have completed GeneSight pharmacogenomic testing, you have received a report that categorizes medications into three color-coded groups. Understanding what each category means helps you have a more informed conversation with your provider about your treatment options.
The Green Category: Use as Directed
Medications in the green category are expected to work as the standard prescribing information describes. Your genetic profile does not suggest any significant issues with how your body will metabolize these medications. This does not guarantee the medication will work for you, as many factors beyond genetics influence treatment response, but it means genetics are unlikely to be a barrier.
The Yellow Category: Moderate Gene-Drug Interaction
Medications in the yellow category may be affected by your genetic profile in ways that could require dose adjustments or increased monitoring. For example, you may metabolize the medication slightly faster or slower than average. Your provider may still prescribe medications from this category but will factor the genetic information into dosing decisions.
The Red Category: Significant Gene-Drug Interaction
Medications in the red category have significant gene-drug interactions that may cause them to be less effective or more likely to produce side effects at standard doses. This does not mean these medications can never be used, but your provider will consider this information seriously when making prescribing decisions.
What GeneSight Results Do Not Tell You
GeneSight tests metabolic genes, not the genes that determine whether a medication will be effective for your specific condition. It can tell your provider whether your body is likely to process a medication normally, but it cannot predict with certainty whether the medication will reduce your symptoms. Think of it as removing genetic barriers to treatment rather than predicting treatment success.
Your provider at Modern Mentality will review your GeneSight results with you in detail and explain how they inform your treatment plan. Contact us to learn more about pharmacogenomic testing.
